Chun Li, Ph.D.
Cancer Systems Imaging
Areas of Research
- Drug Development
Research activities in the laboratory of Chun Li, Ph.D., are primarily focused on two areas: the development of targeted imaging probes for noninvasive characterization of molecular events associated with tumor progression and regression and the development of novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents.
Molecular imaging probes used in nuclear, optical and magnetic resonance imaging modalities are designed to enhance the sensitivity and selectivity of early tumor detection, tumor-marker profiling and the monitoring of early treatment responses.
Targeted drug delivery, on the other hand, uses nanometric drug carriers to selectively deliver anticancer agents to the tumor to maximize their therapeutic efficacy and minimize their toxic side effects to the normal tissues. The long-term goal is to apply the “seek and treat” strategy in the development of targeted imaging/therapeutic agents that will eventually be translated to the clinic to improve the management of cancer through early tumor detection and individualized therapy.
About Dr. Li
Chun Li, Ph.D., is a professor of Cancer Systems Imaging at MD Anderson Cancer Center. He earned his Ph.D. in chemistry from Rutgers University.
Chemistry Laboratory for Imaging Sciences (Li)
John S Dunn Foundation, 7/1/2007-6/30/2024
This grant supports research activities in the Division of Diagnostic Imaging. Activities focus on improved patient management through development of new theranostics and delivery procedures.
GS-441524 is Pharmacodynamically Equivalent to Remdesivir and Pharmacokinetically Superior Drug for the Treatment of COVID-19
NIH/NIAID R21AI159246 (Li), 1/1/2021-12/31/2023
Assessing Imaging Biomarkers for Response to Combined IRE and Anti-PD-1 Immunotherapy
MD Anderson Cancer Center QIAC Partnership in Research Grants Program (Javadi/Li), 5/1/2021-10/30/2023
Theranostic Heterodimer Eph-Targeting Peptides for Ovarian & Breast Cancer, Emerson Collective Cancer Research Fund (Li), 12/17/2021-12/16/2023
Development of Irreversible Electroporation-based Rational Combinations to Potentiate the Activity of Cancer Immunotherapy against Pancreatic Ductal Adenocarcinoma
NIH/NCI R01CA258540 (Li, Wang), 2/1/2022-1/31/2027
IRE-based Rational Combination for Effective PDAC Immunotherapy,
Cancer Prevention & Research Institute of Texas (CPRIT) RP220051 (Li), 3/1/2022-2/28/2025
Theranostic Strategy for Proton Boron Capture Therapy of Pancreatic Cancer (THER-PBCT)
The University of Texas Austin – Portugal Program (Paulo, Li) 5/1/2022-4/30/2023
Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy
NIH/NCI R01 CA257842 (Li, Yang, Chow), 8/1/2022-6/30/2026
The University of Texas MD Anderson Cancer Center
Cancer Systems Imaging
1881 East Road
Unit Number: 1907
Houston, TX 77054-1901
Room Number: 3SCR4.3636
Angela D Lavergne
Senior Administrative Assistant, Cancer Systems Imaging